Article
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
Asia-Pacific journal of clinical oncology - 1 Sept 2012
Wu Yi-Long, Chu Da-Tong, Han Baohui, Liu Xuyi, Zhang Li, Zhou Caicum, Liao Meilin, Mok Tony, Jiang Haiyi, Duffield Emma, Fukuoka Masahiro
Abstract excerpt
AIM: In the IRESSA Pan-Asia Study (IPASS), 1217 patients in East Asia with pulmonary adenocarcinoma who were never-smokers or ex/light-smokers received first-line gefitinib (250 mg/day) or carboplatin/paclitaxel (area under the curve 5/6; 200 mg/m(2) ). Efficacy analyses were pre-planned in patie...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.